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iscal Year 2010 was marked by some major achievements, changes, and exciting 
new directions for the National Center for HIV/AIDS, Viral Hepatitis, STD, and 
TB Prevention, which are presented in this fourth annual report for the center.
One major event was the release of the first National HIV/AIDS Strategy (NHAS) by 
President Obama in July 2010. The new strategy is focused on three overarching 
goals: reducing the number of new HIV infections, increasing access to care for people 
living with HIV, and reducing HIV-related health disparities.
The NHAS was the result of extensive public input, including 14 HIV/AIDS community 
discussions held across the country, as well as an online suggestions process, various 
expert meetings and other inputs. Senior leaders at CDC were involved in a Federal 
interagency working group that reviewed recommendations from the public and worked with the Office of 
National AIDS Policy to develop the NHAS. NCHHSTP has a number of assigned activities under NHAS, 
including improving core surveillance and use of community viral load, enhancing prevention among most 
affected communities, integrating care and prevention, expanding HIV testing and linkage to care services, 
building capacity, developing evidence-based social marketing campaigns, and improving the quality and 
monitoring of all programs.
FY 2010 also marked the completion of another valuable roadmap for NCHHSTP— its strategic plan for 2010­
2015. It sets out our vision and priority activities for NCHHSTP. The plan was the result of a collaborative effort 
by staff in the NCHHSTP Office of the Director, the center's divisions and branches, and other key partners 
within and outside of CDC.
Another key plan released in FY 2010 was the Institute of Medicine's report, Hepatitis and Liver Cancer: A 
National Strategy f o r  Prevention and Control o f Hepatitis B and C. The report provides a roadmap for national 
efforts to prevent the transmission of new infections and to mitigate the adverse health impact of chronic 
infections. NCHHSTP is working to address the report's recommendations.
An event of note during FY 2010 was a CDC reorganization that moved the Global AIDS Program to a new 
Center for Global Health. We are pleased to be a part of this enhanced focus on global health throughout our 
agency, and especially in the Center for Global Health. Even with the departure of GAP, NCHHSTP continues 
a range of international research activities and collaborations. We therefore remain committed to strong 
partnerships with our global health colleagues across the agency and federal government during this exciting 
time of change.
On the domestic front, the epidemics of HIV and other STDs, hepatitis, and TB are large and complex, but we 
have made progress in the last year, including the following:
• New diagnoses and rates of TB dropped dramatically in 2010, declining by more than 10% from the 
previous year.
• Expansion of hepatitis B vaccination programs brought continued declines in acute 
hepatitis B infections.
• Advances in checking for and tracking of hepatitis C infection continue.
• New efforts have started that focus on mobilizing communities to reduce HIV, STD, TB, and hepatitis 
health disparities and promote greater health equity.
• Large investments continue to be made to promote HIV testing, especially in areas with high rates of 
disease among African Americans.









• New resources were directed to HIV prevention through funds from the Affordable Care Act's 
Prevention and Public Health Fund to expand HIV prevention efforts under NHAS, including $11.6 
million to support demonstration projects to identify and implement a combination approach to 
enhance HIV prevention in 12 hard-hit jurisdictions.
• The GYT: Get Yourself Tested campaign aimed at encouraging youth to be tested for STDs as well as 
HIV, continued for a second successful year.
• New prevention programs have been introduced and established programs and approaches refined, 
including collaborative programs that integrate services for more than one disease or risk, begin to 
address the social determinants of health, and put funding in areas where there is evidence of 
improved health.
• New communication technologies have promoted HIV and STD prevention.
• NCHHSTP worked on updating the Guidelines for the Treatment of Sexually Transmitted Diseases, 
which were released in December 2010.
This year's report also highlights NCHHSTP staff. Our Center attracts an exceptionally diverse set of public 
health and support professionals with a range of skills and experience that is perfect to develop and deliver 
evidence-based and high-impact prevention programs, research, and policies. Our expert staff, combined with 
our unique relationships with governmental, non-governmental and private sector partners, form a foundation 
that provides us the opportunity to champion public health and accelerate disease prevention and health 
protection activities.
We will work to meet the standards set by the administration that government should be transparent and 
accountable; participatory and committed to public engagement; and collaborative, acknowledging and acting 
on the fact that the whole is always greater than the sum of its parts. We are committed to communicating 
the right information, at the right time and in the right way, and to our science promoting the delivery and 
implementation of the most effective programs at home and around the world.
Kevin A. Fenton, M.D., Ph.D., F.F.P.H.
Director, N ational Center for HIV/AIDS,
Viral H epatitis, STD, and TB Prevention
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About NCHHSTP
The National Center for HIV/AIDS, Viral Hepatitis, 
STD, and TB Prevention (NCHHSTP) is part of the 
Centers for Disease Control and Prevention (CDC)— 
an agency of the U.S. Department of Health and 
Human Services (HHS).
The National Center for HIV, STD, and TB Prevention 
(NCHSTP) was established in 1994 to bring most 
of CDC's HIV prevention activities together under 
a single organizational home that also includes 
sexually transmitted disease (STD) prevention and 
tuberculosis (TB) elimination programs. In 2000, the 
Global AIDS Program (GAP) was added to NCHSTP 
in response to the global HIV/AIDS epidemic. In 
2006, CDC's Division of Viral Hepatitis was added to 
NCHSTP and the center was renamed the National 
Center for HIV/AIDS, Viral Hepatitis, STD, and TB 
Prevention. In FY 2010, GAP joined CDC's new Center 
for Global Health.
The diseases addressed by NCHHSTP share a number 
of commonalities. They have similar or overlapping 
at-risk populations— including racial and ethnic 
minorities, gay and other men who have sex with 
men, and injection drug users. These diseases also 
have important interactions. Those who are infected 
with certain STDs, such as syphilis or gonorrhea, 
are at greater risk for HIV infection. Likewise, those
who are infected with HIV are far more susceptible 
to TB disease because their immune systems are 
weakened. Similarly, approximately 33% of those 
infected with HIV are co-infected with hepatitis C, 
and 10% are co-infected with hepatitis B.
These diseases also share similar social determinants, 
including poor access to health care, stigma, 
discrimination, incarceration, homelessness, and 
poverty. In the area of prevention and control, 
effective, science-based interventions exist to reduce 
the burden of TB, viral hepatitis, most STDs, and HIV.
As a leader in preventing and controlling HIV 
infection, viral hepatitis, STDs, and TB, NCHHSTP 
applies well-integrated, multidisciplinary programs 
of research, surveillance, risk-factor and disease 
intervention, and evaluation. For example, NCHHSTP 
addresses domestic HIV/AIDS prevention through an 
array of public health activities including monitoring 
the disease's impact, facilitating and supporting 
partnerships, implementing prevention programs, 
conducting intervention research and program 
evaluation, delivering technical assistance to build 
the capacity of organizations to offer prevention 
services, and developing policy and communications 
to support HIV prevention.













NCHHSTP Strategic Plan: Key Priorities
During FY 2010, NCHHSTP finalized a strategic plan 
to guide the center's programs and research from 
2010-2015. The plan was the result of a collaborative 
effort by staff in the NCHHSTP Office of Director, 
the center's divisions and branches, and other key 
partners within and outside of CDC. It outlines key 
objectives and strategies for achieving mutual goals 
with NCHHSTP partners.
The plan outlines six key priorities to provide focus, 
direction, and a way to organize NCHHSTP's work, 
in addition to the center's core mission. They are 
shown below.
Prevention Through Health Care
NCHHSTP will develop, implement, and evaluate 
policies and practices that leverage the health 
care system to improve health through prevention. 
Impending health reform presents an unprecedented 
opportunity for NCHHSTP to work across multiple 
levels (federal, state, local, and global), and 
within and across sectors (public, private, non­
governmental, etc.) to advance strategic priorities 




NCHHSTP will support and promote a syndemic 
approach to prevention by promoting better 
collaboration between programs and supporting 
appropriate service integration at the point of access. 
NCHHSTP will look broadly across its programs, 
and work with our partners, to discover new and 
innovative ways to collaborate and use resources 
wisely and efficiently— taking advantage of multiple 
disciplines and shared knowledge and promoting 
holistic approaches to health protection.
Health Equity
NCHHSTP will reduce health disparities in HIV/AIDS, 
viral hepatitis, STDs, and TB by promoting health 
equity. Many of the populations served by NCHHSTP 
suffer from the stigma attached to their diseases 
or from socioeconomic disparities. It is, therefore, 
imperative for the center to make research, policy, 
and programs in this area a top priority.
Global Health Protection 
and Systems Strengthening
NCHHSTP will optimize global collaborations and 
interactions to enhance the overall effectiveness of 
its international program development and public 
health research. Though much of NCHHSTP's work 
is focused on important and urgent domestic issues, 
it cannot ignore the global interconnectedness 
of societies, population movement, and disease 
epidemiology. NCHHSTP plays an important role in 
protecting the health and well-being of Americans, 
at home and abroad, and it serves as an important 
international partner in efforts to protect and 
improve the health of all people.
Partnerships
NCHHSTP will create and strengthen mutually 
beneficial, strategic relationships with other 
individuals, organizations, and networks that 
strengthen HIV/AIDS, viral hepatitis, STD, and TB 
prevention and control, producing solutions that 
no individual entity working independently can 
accomplish. The center cannot accomplish its mission 
without strong, established partnerships. NCHHSTP 
will lead collaborative efforts with partners to reduce 
the impact of these diseases at home and abroad.
Workforce Development 
and Capacity Building
NCHHSTP will attract, maintain, develop, and utilize 
NCHHSTP's professional workforce to effectively 
promote health and prevention activities. The center 
will work with our partners to assess and support 
critical local staffing needs, as appropriate. We will 
examine and leverage opportunities in an evolving 
health system to support this goal. Additional 
detail on the six strategic goals, with accompanying 
objectives and strategies, are provided in this report.
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A Year in Review: 
Program Accomplishments
To ensure the greatest impact on the HIV/AIDS,
STD, viral hepatitis, and TB epidemics, NCHHSTP 
uses a comprehensive, evidence-based approach 
to prevention that incorporates surveillance, 
research, prevention interventions, and evaluation. 
NCHHSTP's surveillance and research activities 
help to better define and understand the nature 
of the epidemics across the nation, providing vital 
information to develop prevention strategies. The 
center's prevention interventions and capacity­
building efforts are based on behavioral, laboratory, 
and medical science and are designed to reduce 
the spread of HIV/AIDS, STDs, viral hepatitis, and 
TB. Program evaluation and policy research and 
development assess intervention effectiveness and 
refine prevention approaches.
The following sections provide examples of how 
NCHHSTP's programs supported the center's 
strategic plan in FY 2010.
Goal 1: Prevention Through Health Care
HIV and other STDs, viral hepatitis, and TB are 
among the leading causes of morbidity and death 
in the United States and account for substantial 
portions of health care spending. The national focus 
on prevention and wellness provides an opportunity
to address the health conditions NCHHSTP 
emphasizes and to contribute to improving the 
nation's health through evidence-based clinical and 
community prevention and wellness activities.
There is also a new focus on improving the delivery 
of health care services, improving patient health 
outcomes and population health, developing new 
quality measures and disseminating best practices 
in the delivery of quality health care services. By 
establishing or expanding collaborations across CDC 
and with other governmental and non-governmental 
partners, NCHHSTP is working to advance its 
strategic and programmatic imperatives and expand 
opportunities for prevention through health care. 
Below are highlighted accomplishments related to 
this goal.
Expanding HIV Testing for Disproportionately 
Affected Populations
NCHHSTP extended its successful 3-year HIV Testing 
Initiative, which was aimed at African Americans, for 
an additional 3 years and expanded the testing to 
also reach Hispanic men and women, men who have 
sex with men, and injection drug users, regardless 
of race or ethnicity. The initiative also received an 
additional $4.4 million from the Affordable Care Act's 
Prevention and Public Health Fund and $950,000 
from the HHS Minority AIDS Initiative.
In the first 2 years of the testing initiative, more 
than 1.4 million HIV tests were conducted, with the 
majority (62%) among African Americans— who 
were the focus of the original program. More than
10,000 persons newly diagnosed with HIV infection 
were identified, of which about three-quarters were 
reported to have been linked to care and treatment.
Updated STD Treatment Guidelines
The CDC STD Treatment Guidelines are the 
most widely referenced and authoritative source 
of information on STD treatment and prevention 
strategies for clinicians who evaluate persons with 
STDs or those at risk for STDs. For more than 20























years, these guidelines have assisted clinicians 
with effective guidance on the delivery of optimal 
STD care.
In FY 2010, NCHHSTP worked on updating 
the Guidelines for the Treatment of Sexually 
Transmitted Diseases, in consultation with public 
and private sector professionals knowledgeable 
in the management of STDs. An evidence-based, 
systematic review was employed to guide the 
update. The updated guidelines were released in 
December 2010.
Expansion of Expedited Partner Therapy
In recent years, a growing number of states have 
adopted laws authorizing Expedited Partner Therapy 
(EPT), an evidence-based option to prevent patient 
re-infection through management of sex partners 
of patients diagnosed with chlamydia or gonorrhea. 
Some of these states, however, still face challenges in 
implementing EPT. In other states, EPT is either not 
legal or the legality remains unclear.
The Division of STD Prevention and the Centers 
for Law and the Public's Health, a collaborative 
at Johns Hopkins and Georgetown Universities, 
partnered to address legal and policy barriers to 
implementation of EPT. In May 2010, CDC hosted a 
1-day consultation with 20 key consultants, including 
STD directors from states in different phases of 
EPT implementation; experts in public policy, 
law, and ethics; representatives from professional 
organizations; and other partners key to EPT 
implementation. The Division of STD Prevention 
identified EPT implementation barriers and gathered 
input on tools to assist states in developing policies 
to implement EPT.
Expansion of Human Papillomavirus 
Vaccine Recommendation
A high-priority strategic goal for the Division of STD 
Prevention is the prevention of STD-related cancers. 
In 2006, a quadrivalent Human Papillomavirus (HPV) 
vaccine for preventing cervical cancers was licensed 
for use in females and recommended for routine use 
at ages 11 or 12 and catch-up vaccination through 
age 26. In October 2009, a second HPV vaccine— 
the bivalent vaccine— was licensed by the Food and
Drug Administration for use in females, and the 
quadrivalent HPV vaccine was also licensed for use 
in males to prevent genital warts.
The Division led the HPV Vaccine Workgroup 
of the Advisory Committee on Immunization 
Practices (ACIP) in its development of updated 
HPV vaccination recommendations in FY 2010. The 
Division developed cost effectiveness analyses, 
reviewed relevant clinical trial and epidemiologic 
data, and information on vaccine acceptability. ACIP 
recommended that either vaccine could be given 
for routine vaccination of females ages 11 or 12 and 
catch-up vaccination for females through age 26. For 
males, ACIP provided guidance that the quadrivalent 
vaccine may be given to males ages 9 through 26 
years. ACIP recommendations guide clinical practice 
and have direct implications on funding and insurance 
coverage in the country. To see the published 
recommendations in the MMWR (2010;59(20):626- 
629) visit: http://www.cdc.gov/mmwr/preview/ 
mmwrhtml/mm5920a4.htm.
Guidance for Syringe Services Programs
The Consolidated Appropriations Act of 2010 
modified the ban on the use of federal funds for 
needle exchange programs. The Act allowed 
CDC and its partners to more fully implement 
a comprehensive, evidence-based approach for 
reducing HIV infection among injecting drug users, 
who account for approximately 16% of new HIV 
infections.
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In response, NCHHSTP worked with HHS to develop 
guidance for health departments wanting to use FY 
2010 funds for syringe services programs. HHS issued 
technical guidance for HHS agencies and for CDC in 
July 2010. In August, CDC held a Syringe Services 
Program Consultation that brought experts together 
to provide advice on developing programmatic 
guidance on syringe services programs for HIV 
prevention to be implemented by CDC-funded state 
and local health departments. Guidance for the 
program is to be released in early 2011.
Updated Guidelines for Using Interferon 
Gamma Release Assays to Detect TB Infection
In June 2010, the Division of TB Elimination published 
updated guidelines for using Interferon Gamma 
Release Assays (IGRAs) to detect M. tuberculosis 
infection. The Division developed the guidelines 
based on data submitted to the Food and Drug 
Administration (FDA), published reports, and 
expert opinion related to IGRAs. The guidelines 
were updated because two new IGRAs have been 
approved by the Food and Drug Administration and 
peer-reviewed articles describing clinical studies 
of IGRAs have been published since the guidelines 
were originally published in 2005. The guidelines 
also provide recommendations addressing quality 
control, test selection, and medical management 
after testing.
Tuberculosis Trials Consortium
Tuberculosis Trials Consortium (TBTC) is a 
partnership of clinical investigators from the 
CDC, domestic and international public health 
departments, academic medical centers, and 
selected Veterans Administration medical centers 
that conduct research about the diagnosis, medical 
treatment, and prevention of TB infection and 
disease. FY 2010 marked the first year of a new 10- 
year plan for the consortium.
Research sites in the United States and around the 
world will receive more than $90 million over the next 
10 years to develop more effective TB treatments 
through the consortium. From 2010-2020 the focus 
of TBTC will shift from clinical sites located mostly in 
North America to an increased number of sites and 
collaborations located around the world.
TBTC has undertaken nine major trials and 15 sub­
studies. Most recently, TBTC study findings have 
influenced guidelines for treating people co-infected 
with TB and HIV.
Currently, the TBTC is concluding a study of an 
innovative ultra-short-course treatment for latent 
tuberculosis infection (i.e., TB preventive therapy— 
results expected in mid-2011).
National Chlamydia Initiative
In collaboration with Partnership for Prevention, 
NCHHSTP's Division of STD Prevention successfully 
launched the National Chlamydia Coalition (NCC) 
in 2008 to address the continued high burden 
of Chlamydia trachomatis (chlamydia) infection, 
especially among women age 25 and under. NCC 
works to reduce the rates of chlamydia and its 
harmful effects among sexually active adolescents 
and young adults.
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Over the past year, the NCC awarded 10 mini­
grants to address barriers to chlamydia screening, 
commenced a new evaluation workgroup and 
research subcommittee, and explored the use and 
influence of social media (e.g., Twitter and Facebook) 
to reach patients and providers. The NCC is also 
working to expand its monthly online newsletter, 
NCC News, which features up-to-date research, 
publications, and news on chlamydia and related 
areas of interest. For more information on the NCC 
visit http://ncc.prevent.org/.
In addition, in May 2010, Division of STD Prevention 
scientists participated in the CDC Public Health 
Grand Rounds session, "Chlamydia Prevention: 
Challenges and Strategies for Reducing Disease 
Burden." The session raised awareness of chlamydia 
prevention within CDC. It focused on current efforts 
to reduce the burden of chlamydia and addressed the 
public health challenges associated with chlamydia. 
To view the Grand Rounds or read more, visit: www. 
cdc.gov/about/grand-rounds/archives/2010/05-May. 
htm.
Better Hepatitis Prevention 
Through Communication Research
The Division of Viral Hepatitis, with support from the 
NCHHSTP Health Communication Science Office, 
conducted formative research with groups at risk for 
viral hepatitis. The purpose was to explore different 
risk groups' knowledge and attitudes related to 
hepatitis and to pretest educational materials.
Focus groups were conducted in Boston, Chicago, 
and Houston with four separate audiences: Asian
Americans, African Americans, gay men, and persons 
in the general population. Participants included men 
and women between the ages of 45 and 64.
Findings from the focus groups revealed that 
consumers from all the audience segments are 
largely unaware about viral hepatitis, a finding 
echoed by the recently released Institute of Medicine 
report. There was some awareness that different 
types of hepatitis exist, but little to no understanding 
of the differences between types. There was a great 
deal of misinformation about symptoms.
For example, many participants believed that that 
no symptoms indicated no infection, while others 
believed that without symptoms, the disease is not 
detectable. Most participants were unsure who might 
be at risk for viral hepatitis. Few people in any of the 
groups knew that viral hepatitis is a leading cause of 
liver cancer. The Division of Viral Hepatitis is using 
these findings to plan future educational strategies, 
to improve its website, and to improve other 
educational materials.
NCHHSTP Web Metrics Dashboard
The Health Communication Science Office worked 
with communication staff throughout the center 
to develop an NCHHSTP Web Metrics Dashboard.
This Dashboard provides a yearly overall snapshot 
of Web activity across the entire center, including 
who is visiting and how they interact with NCHHSTP 
topic areas and each of the four division sites. The 
Dashboard provides three types of measurements: 
visitor behavior on the sites, customer satisfaction 
with the sites, and audience details of visitors to 
the sites.
The Dashboard indicated that in 2009, NCHHSTP's 
Web pages had more than 57 million page views 
and included three of the top 10 pages on CDC.gov: 
"STD Facts— Genital Herpes," " STD Facts— Human 
papillomavirus (HPV)," and "STDs— Information 
from CDC."
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Goal 2 : Program Collaboration 
and Service Integration
For years, many national organizations and CDC 
grantees have called for better integration of 
services provided by related programs, especially 
of prevention activities related to HIV/AIDS, other 
sexually transmitted diseases, viral hepatitis, and 
tuberculosis. Public health leaders, care providers, 
and prevention partners are continually striving to 
increase their ability to respond to changing disease 
epidemiology, eliminate missed opportunities, and 
meet the needs of communities and populations at 
risk for multiple infections.
Program collaboration and service integration 
(PCSI) is a mechanism for organizing and blending 
interrelated health issues, activities, and services 
to facilitate comprehensive delivery of services. 
NCHHSTP is looking broadly across program areas to 
implement ways to collaborate, using epidemiologic 
data to identify opportunities to intervene in the 
transmission of multiple infections in a coordinated 
way. NCHHSTP published a white paper on PCSI in 
December 2009 (available at http://www.cdc.gov/ 
nchhstp/Publications/).
Following are examples of PCSI accomplishments 
during FY 2010.
Addressing Syndemics Through 
PCSI Funding Opportunity Announcements
NCHHSTP awarded $6.2 million in funds to six 
health departments— New York City, North Carolina, 
Philadelphia, San Francisco, Texas, and Washington, 
D.C., — to plan, scale up, and implement PCSI 
activities. The awards aim to increase collaboration 
among programs and integration of prevention, 
testing, and treatment services for these infections, 
which may be interrelated due to characteristics such 
as risk, transmission, or other factors.
With NCHHSTP guidance, each area will tailor its 
project to meet local needs, taking into account 
prevalence of disease, number of new infections, and 
which communities are most impacted. The projects 
will be monitored and evaluated by NCHHSTP on an 
ongoing basis to identify innovative and effective 
evidence-based strategies, programs, and services 
that can serve as future models for other health 
departments across the country.
PCSI Webcast, May 15, 2010
On May 10, 2010, CDC hosted a live webcast on 
the PCSI White Paper (available at http://www.cdc. 
gov/nchhstp/programintegration/Default.htm). The 
webcast included presentations from HIV/AIDS, viral 
hepatitis, STD, and TB leaders at the national, state, 
and local levels. Almost 600 attendees— twice the 
number that normally view webcasts— from various 
organizations joined the webcast to learn more about 
PCSI and how NCHHSTP and partners are working 
together at all levels to implement PCSI into their 
public health efforts. In addition to participants in 
the United States, the webcast had attendees from 
Australia, Belgium, Namibia, Columbia, and Canada.
Data Security and Confidentiality Consultation
On June 28, 2010, NCHHSTP convened a consultation 
with surveillance leaders from local HIV, viral 
hepatitis, STD, and TB surveillance programs 
across the United States, as well as national partner 
organizations. Participants provided feedback on 
draft Security and Confidentiality Guidelines, which 
were developed to improve surveillance data security 
across disease disciplines and to promote data sharing 
across programs. The draft guidelines cover data 
collection, storage, sharing, and use with the intent of 
removing many of the barriers to data sharing.
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Goal 3: Health Equity
NCHHSTP strives to improve the health of 
populations disproportionately affected by HIV, viral 
hepatitis, STDs and TB, and related diseases and 
conditions. The Office of Health Equity leads the 
effort to improve the health of populations 
experiencing health inequities. NCHHSTP's Division 
programs also support this goal, for example, 
by providing essential surveillance data about 
populations that are most at risk.
Social Determinants of Health Approach
Scientific evidence shows that genetic predisposition 
and risk behaviors only partially explain why some 
people become sick and others do not. Many chronic 
and infectious diseases cluster in populations that 
experience social and economic constraints to good 
health. In recognition of the effect these constraints 
have on health, NCHHSTP is incorporating social 
determinants of health (SDH) into its work.
Social determinants of health are the economic 
and social conditions that influence the health of 
individuals, communities, and jurisdictions as a 
whole. They determine the extent to which a person 
possesses the physical, social, and personal resources 
to identify and achieve personal aspirations, satisfy 
needs, and cope with the environment. The resources 
include, but are not limited to, conditions for early 
childhood development; education, employment, 
and work; food security, health services, housing, 
income, and income distribution; social exclusion; 
the social safety net; racism and discrimination of all 
forms; and unemployment and job security.
Promoting health equity is aimed at reducing 
disparities in diseases among persons who experience 
challenges and limitations for optimal physical and 
psychological health, opportunities for stable life 
conditions, and access to adequate health care. This 
is a new direction for American public health.
Informed by the findings of an external consultation 
held with national experts in December 2008, 
NCHHSTP developed a number of strategies to
(1) increase awareness of the importance of SDH,
(2) advance the science of SDH, and (3) develop a
framework for future policy decisions that will build 
capacity for addressing SDH in center-wide public 
health activities. NCHHSTP conducted a number of 
activities in FY 2010 that furthered its work the area 
of health equity and SDH. These are described below.
Report on Social Determinants 
of Health Activities
NCHHSTP produced a first ever Report on Activities 
Related to the Social Determinants of Health, Fiscal 
Year2009, which details center and Division SDH 
activities conducted in FY 2009. The report provides 
a baseline for monitoring SDH activities. The goal 
of future versions of this report is to assess the 
allocation of programmatic, research, and other 
center resources by categories of SDH and provide 
center-wide guidance on gaps in SDH.
Release of White Paper 
on Social Determinants of Health
NCHHSTP also developed a white paper on SDH in 
FY 2010. This document (available at http://www. 
cdc.gov/socialdeterminants/docs/SDH-White- 
Paper-2010.pdf ) provides an official set of proposals 
that will be used for policy development to address 
health disparities incorporating an SDH framework.
It includes recommendations for advancing notions 
of health equity and social determinants in six critical 
public health functions. In the white paper, NCHHSTP 
commits to
• incorporating SDH into existing research and 
surveillance activities, and to developing and 
evaluating approaches to garner scientific evidence;
• using new technologies in health communication 
and marketing to increase knowledge and 
awareness of SDH and health equity among 
stakeholders;
• finding opportunities to address health inequities 
and SDH through health policy and other sector 
policy development;
• addressing SDH in prevention program activities, 
especially in interventions;
• building capacity to address SDH in science, in 
programs, and with partners nationwide; and
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• seeking opportunities to enhance partnership 
activities in consultation with affected 
communities; territorial, tribal, state and local 
health departments; other governmental, 
non-governmental, and community-based 
organizations.
Issuance of Public Health Reports Supplement
NCHHSTP spearheaded the issuance of the Public 
Health Reports supplement on "Addressing Social 
Determinants of Health in HIV/AIDS, Viral Hepatitis, 
Sexually Transmitted Diseases, and Tuberculosis," 
published in June 2010. This special issue focuses on 
innovations and advances in incorporating an SDH 
framework for addressing the interrelated epidemics 
of HIV, sexually transmitted infections (STIs), viral 
hepatitis, and TB in the United States and globally.
Development of Educational Materials to 
Advance Health Equity
NCHHSTP has developed various educational 
materials to better inform the CDC community 
and the public about health equity and SDH. These 
materials include a glossary of terms regarding health 
equity and SDH, a fact sheet with frequently asked 
questions, and a training slide set.
Staff developed a guidance document for monitoring 
SDH annually. The document recommends key 
variables to monitor and existing external data sets 
to use in conjunction with disease surveillance data 
and establishes clear guidance for measuring and 
reporting SDH. In addition, staff developed statistical 
methods to model SDH using AIDS surveillance data 
and the American Community Survey Data (a U.S. 
Census product).
Testing a Tool for Physicians Recording 
Patients' Sexual History
NCHHSTP's Division of STD Prevention and Division 
of HIV/AIDS Prevention are testing a new tool for 
physicians to use in recording the sexual history of 
African-American men— a group which has a higher 
prevalence of syphilis and other STDs compared with 
other groups. The divisions have been collaborating 
with physicians associated with the National Medical 
Association, as well as health care providers who 
work in high HIV/STD incidence areas.
Advancing a Dialogue on Sexual Health
During FY 2010, several NCHHSTP and CDC divisions 
and key external partners continued efforts to 
advance the dialogue and action on sexual health 
and responsible sexual behaviors in the United 
States. NCHHSTP organized and hosted a technical 
consultation in April 2010 of external stakeholders 
to provide feedback on public health approaches 
to advancing sexual health. This approach is also 
supported through the National HIV/AIDS Strategy.
Other NCHHSTP activities include a continuing 
effort to compile and publish systematic reviews 
of published sexual health interventions and sexual 
health strategies in other countries, initiation of a 
health communication project to develop optimal 
language to describe a sexual health framework, 
exploration of the formation of a dynamic coalition of 
public and private sector partners, and consideration 
of commissioning an Institute of Medicine report with 
collaborative support by partners.
Analysis Shows Disproportionate Impact 
of HIV and Syphilis Among U.S. Gay and 
Bisexual Men
NCHHSTP's Division of HIV/AIDs Prevention 
estimates that approximately 1.1 million adults and 
adolescents were living with HIV infection in the 
United States at the end of 2006 and that gay and 
bisexual men of all races, African Americans, and 
Hispanics/Latinos were most heavily affected. An FY 
2010 Division of HIV/AIDS Prevention and Division of 
STD Prevention data analysis shed further light on 
the disproportionate impact of HIV on men who have 
sex with men (MSM) in the United States.
The analysis, presented at CDC's 2010 National STD 
Prevention Conference, estimated that the rate of 
new HIV diagnoses among MSM is more than 44 
times that of other men and more than 40 times that 
of women. The range was 522-989 cases of new HIV 
diagnoses per 100,000 MSM vs. 12 per 100,000 other 
men and 13 per 100,000 women. The rate of primary 
and secondary syphilis among MSM is more than 46 
times that of other men and more than 71 times that 
of women, the analysis says. The range was 91-173 
cases per 100,000 MSM vs. 2 per 100,000 other men 
and 1 per 100,000 women.
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While CDC data have shown that gay and bisexual 
men make up the majority of new HIV and syphilis 
infections for several years, CDC estimated the rates 
of these diseases for the first time based on new 
estimates of the size of the U.S. population of MSM.
NCHHSTP is also in the early stages of planning for 
estimates among heterosexuals. Ultimately, these 
data can be used to better inform national, state, 
and local approaches to HIV and STD prevention to 
ensure that efforts are reaching the populations in 
greatest need.
Monitoring HIV Prevalence, Unrecognized 
Infection, and HIV Testing Among Men Who 
Have Sex with Men
In September 2010, CDC published an MMWR 
article describing HIV prevalence of 19% among 
MSM interviewed and tested for HIV infection 
during 2008 and reported to the National HIV 
Behavioral Surveillance System (NHBS). NHBS is 
conducted in 21 U.S. cities and is used to monitor 
the prevalence of, and trends in, HIV-related risk 
behaviors, HIV testing, and use of HIV prevention 
services among populations at high risk for HIV 
infection, including MSM, users of injection drugs 
(IDU), and heterosexuals at increased risk for HIV 
infection.
Division of HIV/AIDS Prevention analyses of NHBS 
data collected in 2008 reveal that HIV prevalence 
remains high among MSM and reinforce the data 
estimating HIV and syphilis incidence for MSM. The 
data show that many MSM are unaware they are 
infected, and minority MSM are disproportionately 
affected by the HIV epidemic. Of all MSM surveyed 
and tested, 19% were infected with HIV and 44% of 
those infected were unaware of their infection. HIV 
prevalence among white MSM was 16%, 18% among 
Hispanic MSM, and 29% among black MSM. Black 
and Hispanic MSM were more likely than white MSM 
to be unaware of their HIV infection; 26% of white 
MSM with HIV infection did not know their status 
compared with 46% of Hispanic MSM and 59% of 
black MSM. Of MSM with unrecognized infection, 
54% had not been tested within the preceding 12 
months, but 46% reported having had an HIV test 
in the preceding 12 months, indicating they had 
acquired HIV recently.
NHBS will be critical for monitoring the impact of the 
National HIV/AIDS Strategy (http://www.whitehouse. 
gov/administration/eop/onap), which focuses on 
reducing HIV incidence, increasing access to care 
and optimizing health outcomes, and reducing HIV- 
related health disparities.
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Urban Poor in the United States 
have High Rates of HIV
NCHHSTP released a first-of-its-kind analysis 
showing that 2.1% of heterosexuals living in high- 
poverty areas in 23 major U.S. cities are infected 
with HIV— more than four times the national average 
(0.45%). The data also showed an inverse correlation 
between income and HIV prevalence among 
heterosexuals living in these poor urban areas: the 
lower the income, the higher the prevalence of HIV.
The HIV prevalence in high poverty urban areas 
is severe enough to be considered a "generalized 
epidemic" (defined by UNAIDS as an overall HIV 
prevalence in the general population of more than 
1%). Poverty was the single most important factor 
in predicting HIV infections among heterosexuals in 
these areas. No statistically significant differences 
in HIV prevalence among heterosexuals by race or 
ethnicity were found in these low-income, urban 
areas. These findings from the Division of HIV/AIDS 
Prevention study remind us that we cannot look at 
HIV disease in isolation from the environment in 
which people live.
TB Rates Declined Dramatically
The U.S. TB rate decreased by more than 10% in 
2009 from the previous year. A total of 11,540 TB 
cases were reported in the United States according 
to data from the National TB Surveillance System.
The TB rate was 3.8 cases per 100,000 population, a 
decrease of 11.4% from the rate of 4.2 per 100,000 
population reported for 2008. TB case counts and 
rates decreased substantially among both foreign- 
born and U.S.-born persons, although foreign-born 
persons and racial/ethnic minorities continued to 
have TB disease disproportionate to their respective 
populations. The 2009 rate showed the greatest 
single-year decrease ever recorded and was the lowest 
recorded since national TB surveillance began in 1953.
Due to the unexpected steep decline in TB cases, the 
Division of Tuberculosis Elimination investigated and 
analyzed the decline to ensure the decline was not 
a function of underreporting or other problems. No 
such evidence was found. Investigations in two states 
also did not find evidence that health care providers 
were less likely to consider the diagnosis of TB in 
2009 compared with previous years. Nor were there
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changes in laboratory diagnostic procedures that 
might explain the decline. The decline in reported TB 
may be associated with improvements in TB control 
as well as changes in immigration patterns and health 
care seeking during a time of economic recession.
Estimating Burden of STDs Among Young 
Women in the United States
A study published in FY 2010 highlighted the 
burden of STDs among women in the United States. 
Using data from the National Health and Nutrition 
Examination Survey (NHANES), researchers in 
the Division of STD Prevention, for the first time, 
estimated the prevalence of the most common STIs
among a representative sample of 14-19 year-old 
females in the United States. The study found that 
24.1% of female adolescents had at least 1 of the 5 
STIs and STI prevalence was 37.7% among sexually 
experienced girls.
HPV was the most common STI, followed by 
chlamydia. The study also showed that STIs begin to 
be acquired soon after sexual initiation and with few 
sex partners. These findings indicate the need for 
early and comprehensive sexual health education, 
routine HPV vaccination at the age of 11 to 12 years, 
and chlamydia screening of sexually active female 
adolescents.
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Goal 4: Global Health Protection and 
Health Systems Strengthening
NCHHSTP is working to maximize global health 
protection and strengthen global health systems 
by fostering programmatic relationships among 
its divisions that conduct international activities. 
Ensuring active collaboration between NCHHSTP 
divisions leverages center and CDC resources and 
maximizes health impact.
Leading Global Perinatal 
Integration Workgroup
NCHHSTP is co-chairing the CDC Global Perinatal 
Integration Working Group. The cross agency 
working group supports implementation and 
evaluation of interventions aimed at protecting the 
health of mothers and infants during pregnancy, 
delivery, infancy, and early childhood. Established 
in 2007 to promote collaboration across NCHHSTP 
divisions implementing interventions during 
pregnancy, the Global Perinatal Integration 
Workgroup was broadened to engage membership 
from other CDC programs working in global maternal 
and newborn child health. The workgroup seeks to 
advance the science and delivery of comprehensive 
and appropriately integrated maternal and newborn 
child health services globally.
The workgroup's priority activity for 2010 was to 
promote implementation science around integrated 
maternal and newborn child health activities by 
conducting evidence-based evaluations to assess the 
challenges and effectiveness of integrating maternal 
and newborn child health interventions in developing 
countries.
International Activities: Global STD Control 
and Prevention
NCHHSTP scientists in the Division of STD 
Prevention continue to collaborate with other 
nations, the World Health Organization (WHO), 
and other international partners to prevent STDs 
globally through: conducting clinical, laboratory, and 
programmatic research in support of priority areas 
such as the global elimination of congenital syphilis 
and new STD surveillance; supporting rolling out 
HPV vaccine in low-income, high burden nations;
and promoting laboratory technologies of emerging 
concern, such as global surveillance of highly 
resistant strains of Neisseria gonorrhea.
As part of its long-term collaboration with the 
WHO Department of Reproductive Health 
Research, NCHHSTP technical experts supported 
the development of an Investment Case f o r  the 
Global Elimination o f Congenital Syphilis. This 2010 
document promoting congenital syphilis screening 
and treatment in the context of better maternal and 
child health and stronger health systems outlines 
the global burden of congenital syphilis, including 
prevalence of untreated maternal infections, and 
estimates adverse pregnancy outcomes worldwide. 
Division of STD Prevention scientists also continue to 
lead the development of the elimination initiative's 
global monitoring and evaluation activities. In 2010,
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indicators measuring congenital syphilis program 
progress and impact were formally adopted by 
WHO's Regional Offices, paving the way for syphilis 
indicators to be integrated into existing health 
services monitoring systems.
NCHHSTP also continues to support WHO in 
strengthening regional surveillance by assessing the 
global spread of gonorrhea caused by cephalosporin- 
resistant strains, including development of 
standardized protocols in 2010. In addition, Division 
of STD Prevention laboratory scientists provide 
technical assistance to the Global AIDS Program 
to establish a network of regional and sub-regional 
reference laboratories equipped to provide STD 
laboratory training and reference functions 
required to enhance STD surveillance, program 
improvement, and monitoring and evaluation.
During the past 5 years, CDC actively supported the 
successful implementation of the integrated sexual 
behavioral and biomarker surveillance studies in 
Honduras (2005), El Salvador (2008), and Nicaragua 
(2010). Additionally in 2009-2010, CDC conducted 
the assessment of STD laboratory capacity at 
Guatemala, Nicaragua, and Panama to decentralize 
the STD laboratory capacity in the regional and sub­
regional levels.
Reduction of Occupational TB 
in the Russian Federation
NCHHSTP's Division of Tuberculosis Elimination is a 
partner in an effort to help reduce TB transmission in 
Vladimir, Russia, (at the Vladimir Center of Excellence 
for Tuberculosis Infection Control at the Vladimir 
Oblast Tuberculosis Dispensary) as well as other 
areas of the country. The risk of TB among health 
care workers in the Russian Federation exceeds the 
risk in the general population more than twentyfold. 
Additionally, the Russian Federation has among the 
highest levels of multidrug-resistant TB (MDR TB) 
in the world. The occurrence of TB among health 
care personnel and prison guards in Vladimir, Russia, 
heightens anxiety about institutional transmission.
The program is a partnership with the Vladimir 
Oblast Administration, the Division of Tuberculosis 
Elimination, the U.S. Agency for International 
Development, Central Tuberculosis Research 
Institute, and WHO-Moscow. The Vladimir Center 
serves as an infection control training hub for 
Russia and other members of the Commonwealth 
of Independent States. The center is involved in 
teaching, monitoring, and implementing infection 
control measures which protect people in health 
facilities, homeless shelters, and prisons from 
nosocomial TB transmission.
Several infection control interventions have been 
implemented at the Vladimir Oblast Tuberculosis 
Dispensary. The Division of Tuberculosis Elimination 
conducted an infection control training course 
that included respirator fit testing. Following the 
course, the Russian Dispensary staff developed an 
infection control program for their new location that 
included measures such as improving the ventilation 
system, installing biosafety equipment, giving staff 
respirators, training staff in use of respirators, and 
separating patients by infectious status.
As a result of these Infection Control interventions, a 
remarkable reduction in occupationally acquired TB 
was achieved in the Oblast TB Dispensary (from 1,083 
to 166 new cases per 100,000 during the first 5 years 
of the program, and no new cases of occupational TB 
were reported during 2008-2009).
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Global Hepatitis E Virus (HEV)
Leading experts from Asia, Europe, Africa, and North 
America gathered in Seoul, Korea, in September 2010 
for the first International Symposium on Hepatitis 
E, which was organized by NCHHSTP's Division 
of Viral Hepatitis and the International Vaccine 
Institute in collaboration with WHO. The symposium 
offered participants the opportunity to share current 
data on hepatitis E epidemiology, disease burden, 
diagnostics, and vaccines. The overall objective of 
the symposium was to establish an international 
consortium to accelerate the development and 
implementation of HEV control and prevention 
measures through standardized approaches.
Outcomes of the symposium included publication 
of the symposium proceedings in a peer-reviewed 
supplement to a scientific journal and generation of a 
research agenda, including strategies for accelerated 
development and implementation of hepatitis E 
vaccines.
International AIDS Conference, Vienna
NCHHSTP co-sponsored a satellite session at the 
International AIDS Conference 2010 in Vienna with 
the Public Health Agency of Canada. The session 
focused on "MSM and HIV/AIDS Prevention and Care: 
Challenges and Opportunities in High Resource/
Low Prevalence Countries." The session featured 
speakers from NCHHSTP, the Public Health Agency 
of Canada, the National Institute for Public Health 
and the Environment in the Netherlands, and 
Deutsche AIDS-HILFE in Germany. The presenters 
discussed challenges, successes, and strategies for 
HIV prevention among MSM. NCHHSTP researchers 
also gave a number of other presentations at 
the International AIDS Conference, including a 
presentation on NCHHSTP's analysis showing high 
rates of HIV infection among heterosexuals living in 
high-poverty, urban areas of the United States and 
preliminary results from an NCHHSTP clinical study 
that found no significant safety concerns regarding 
tenofovir taken daily for HIV prevention among gay 
and bisexual men.
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Goal 5: Partnerships
NCHHSTP engages partners to improve prevention 
of HIV/AIDS, viral hepatitis, STDs, and TB. NCHHSTP 
works with government and non-government 
partners at the community, state, national, and 
international levels. These partnership activities 
include funding prevention efforts, demonstration 
projects, capacity-building efforts, and surveillance 
activities in state, local, and territorial health 
departments, as well as community-based and 
national organizations. NCHHSTP coordinates its 
efforts with other federal agencies, including those 
within HHS.
Supporting the National HIV/AIDS 
Strategy Through the Prevention 
and Public Health Fund
On July 13, 2010, President Obama released the 
new National HIV/AIDS Strategy. The strategy 
is an across-the-board approach that calls for a 
more coordinated national response to achieve 
three primary, concrete goals: (1) reduce new HIV 
infections, (2) increase access to care and optimize 
health outcomes for people with HIV/AIDS, and (3) 
reduce HIV-related health disparities.
Following the release of the strategy, NCHHSTP 
worked with colleagues across CDC, HHS, and 
the federal government to complete detailed 
departmental operational plans for implementing 
the strategy.
To support the strategy, CDC received an allocation 
of $30 million from the Affordable Care Act's 
Prevention and Public Health Fund to expand HIV 
prevention efforts under the National HIV/AIDS 
Strategy. This includes $21.6 million in grants to 
state and local health departments. The funding was 
to help to further focus HIV prevention on high-risk 
populations and communities, as well as fill critical 
gaps in data, knowledge, and understanding of the 
epidemic.
Enhanced Comprehensive HIV Prevention 
Planning: Cooperative agreements totaling $11.6 
million support demonstration projects to identify 
and implement a "combination approach" to enhance 
effective HIV prevention programming in 12 hard- 
hit areas across the country. These efforts will both 
supplement existing programs in these communities 
and help jurisdictions to better focus efforts on key 
at-risk populations and fulfill unmet needs.
The 12 jurisdictions funded in the first year for 
these efforts were Chicago, the District of Columbia, 
Florida, Georgia, Houston, Los Angeles, Maryland, 
New York City, Philadelphia, Puerto Rico, San 
Francisco, and Texas. The average award was 
approximately $960,000.
Increasing HIV testing: $4.4 million will allow CDC 
to further expand its successful HIV testing initiative, 
which was mentioned previously in this report.
Filling critical data gaps: $5.6 million will 
enhance local area data collection to provide critical 
information to better monitor and target future HIV 
prevention and treatment programs. Specifically, 
the new funds allow areas to monitor disease 
indicators among HIV-infected populations to better 
understand access to care, prevention, and treatment 
services. Filling these data gaps is a step toward 
monitoring community HIV viral load— a surveillance 
technique using a biological marker for potential HIV 
transmission at the population level. Recent studies 
suggest that increased coverage with combination 
antiretroviral therapy could reduce HIV transmission 
at the population level through mediating viral load. 
CDC is exploring how community viral load could be 
monitored nationally.
The remainder of the funding supports additional 
activities for HIV prevention:
Supporting evaluation for new activities: $6.6 
million will support the evaluation and monitoring 
of combination prevention approaches and other 
activities. Funding will also establish a Web-based 
survey to quickly identify and respond to trends in 
risk behavior and exposure to HIV prevention services 
among MSM.
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Prioritizing underserved populations: $1 million 
will support work with tribal communities to 
improve HIV prevention and program integration for 
American Indians/Alaska Natives.
Expanding the Reach 
of Viral Hepatitis Programs
The CDC Foundation is working with NCHHSTP to 
develop new private sector partnerships to enhance 
the center's programs. A new partnership initiated in 
FY 2010 through the Foundation is the Viral Hepatitis 
Action Coalition. The Viral Hepatitis Action Coalition, 
launched in January 2010, is comprised of private- 
sector organizations committed to supporting high 
priority research, education, and program evaluation 
projects initiated by the Division of Viral Hepatitis.
In addition to providing funding for specific projects, 
Coalition members also will support CDC by sharing 
research data, connecting CDC to appropriate 
stakeholders and networks, and providing feedback 
on the information and tools needed in the field to 
respond to the recommendations outlined in the 
Institute of Medicine report. Initially organized with 
participation from four members, the Coalition now 
has the support of nine members.
Expansion of Act Against 
AIDS Campaign Activities
The Act Against AIDS campaign, launched in FY 
2009, is the first federally funded, national HIV 
prevention campaign in more than two decades.
Act Against AIDS is a 5-year, multifaceted, national 
communication campaign intended to refocus 
national attention on the domestic HIV/AIDS 
epidemic and reduce HIV incidence in the United 
States. The campaign's first phase was gV2 Minutes, 
which delivered the simple message to the general 
public that in the United States, every 9V2 minutes, 
someone's brother, mother, sister, father, or neighbor 
is infected with HIV— the virus that causes AIDS. In 
the 18 months since Act Against AIDS was launched, 
the campaign has garnered more than 1.2 billion 
impressions through media placements, internet 
advertising, and donated billboard and out-of-home 
advertising. The gV2 Minutes TV public service 
announcements had a total of more than 513 million 
impressions.
Two new campaign phases aimed at African 
Americans were implemented in FY 2010. One phase 
encourages African-American MSM to be tested for 
HIV on a regular basis. Another phase, iknow, was 
aimed at African-American men and women aged 18 
to 24. The i know  campaign represented NCHHSTP's 
first HIV prevention campaign using social media 
to reach a specific population and was designed to 
encourage young African-American adults to talk 
openly and often about HIV, online and off. The i 
know  phase featured Web videos of celebrities such 
as Jamie Foxx, radio PSAs, a Facebook fan page, live 
Twitter feeds, and other platforms intended to create 
an informative dialogue about HIV and what can be 
done to prevent it. At launch, i know garnered more 
than 45 million news media impressions.
In June 2010, NCHHSTP launched HIV Screening. 
Standard Care, a phase of the Act Against AIDS 
national communication campaign designed to 
help physicians make HIV testing a routine part 
of medical care. The program provides tools and 
resources to primary care providers for incorporating 
HIV testing into primary care settings, including 
an annotated physician's guide with CDC's testing 
recommendations, a patient brochure and poster 
explaining the need for HIV screening, and a new 
webpage where physicians can get more information.
In FY 2010, NCHHSTP expanded its successful Act 
Against AIDS Leadership Initiative (AAALI)— a 
partnership of leading national organizations 
designed to increase HIV prevention efforts. 
NCHHSTP increased its funding from $10 million to 
$16 million over 6 years and broadened its scope to 
include eight additional organizations to help fight 
HIV among African Americans, Latinos, and gay 
and bisexual men— the populations hardest hit by 
HIV. When launched in 2009, the initiative brought 
together some of the nation's foremost African- 
American organizations to intensify HIV prevention 
efforts in black communities since African Americans 
are the racial group that bears the heaviest burden of 
HIV in the United States.
Within its first year, AALI partners coordinated nearly 
1,400 outreach events, engaged nearly 400 affiliates 
across the United States in prevention activities, and 
reached millions more with HIV prevention messages
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through conferences, advertisements, and media 
stories.
Get Yourself Talking
NCHHSTP is also using new media in other 
communications efforts. Building on the success 
of the GYT: Get Yourself Tested campaign initiated 
in 2009, the Division of STD Prevention worked 
with its partners, Kaiser Family Foundation, MTV 
Networks, and Planned Parenthood Federation 
of America, to expand the campaign messages to 
include "Get Yourself Talking" in April 2010, STD 
Awareness Month. The enhanced campaign is a result 
of formative research and message testing with the 
target audience, a key contribution of Division of 
STD Prevention scientists to this critically important 
partnership. Using on-air, online, and traditional media 
strategies, the campaign reaches out to young people 
with an empowering, action-oriented message: GYT: 
Get Yourself Tested. Get Yourself Talking. This is the 
first national campaign aimed at encouraging youth to 
be tested for STDs as well as HIV.
In sentinel clinics in April 2009, the number of female 
clients tested for chlamydia and gonorrhea increased 
by 18%, while the number of male clients being tested 
increased by over 35% compared with April of the 
previous year. Additionally, 2009 data indicated the 
largest volume of chlamydia testing ever recorded by 
the national Infertility Prevention Project. The uptake 
in testing was additionally impressive because the 
positivity rate indicates that the campaign reached 
those needing to be tested for STDs.
The message encouraging youth to, "Get Yourself 
Tested and Get Yourself Talking," is supported 
by a wide variety of tools available online and for 
download by clients or clinic staff. The campaign 
includes videos and print material describing how 
to discuss STD testing with a health care provider, 
and similar materials for talking with sex partners 
about STD testing. The campaign also provided web 
resources for finding STD testing locations (www. 
findstdtest.org); thus, providing a one-stop shop for 
information, resources, and helpful tips for taking 
action. Additionally, the campaign provided online, 
customizable promotional materials to use with local 
populations. A major effort to increase the reach
to colleges and Indian reservations appears to have 
been successful, with data still being analyzed.
Collegiate Contest
During STD Awareness Month, the Division of STD 
Prevention executed and produced a collegiate 
campaign, "Get Tested. Make it Contagious,"that 
employed new and traditional media approaches to 
reach 18-25 year-olds on their campuses and in the 
surrounding communities and encourage them to 
get tested for STDs. Three historically black schools 
in Atlanta launched the campaign: Clark Atlanta 
University, Morehouse College, and Spelman College. 
The campaign centered around a free STD testing 
day hosted by the school's student health center.
The campaign included flyers, palm cards, banners, 
Facebook advertisements, and a YouTube video.
As a result of the campaign, more than 200 students 
were tested across the three campuses, with each 
school reporting significant increases over their 
average daily number of STD tests. The evaluation 
demonstrated that communicating through multiple 
channels, incorporating both new media and 
traditional outreach methods, may be effective for 
reaching college students.
Twitter Town Hall on HIV Testing Day
National HIV Testing Day is an annual observance 
intended to help normalize and routinize HIV 
testing as part of an overall HIV prevention strategy. 
Activities for the National HIV Testing Day are led 
by the National Association of People with AIDS 
(NAPWA). For National HIV Testing Day 2010, CDC, 
CDC's National Prevention Information Network, 
NAPWA, and AIDS.gov decided to take a look at 2.0 
technologies that have redefined the landscape for 
information connections and partnership building. 
Together, they began a new venture in technology: a 
Twitter Town Hall.
The Twitter Town Hall was held on June 3, 2010.
The event brought CDC leaders and staff, federal 
and national partners, state and local health 
departments, community-based organizations, 
individuals, and media together in a fast-paced 
and lively conversation whose impact is still being 
realized.
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There were approximately 1,000 tweets during the 
Town Hall from 145 separate Twitter accounts. The 
potential reach of the Town Hall was estimated 
at 243,000 (representing the total number of 
followers for the 145 Town Hall participants). People 
tweeted about National HIV Testing Day plans and 
promotions, facts and figures, and shared ideas for 
collaboration. The success of this event showed the 
power of new technology to bring together diverse 
and varied participants with the same goal— to end 
HIV— along with the opportunity for community­
building and collaboration in a virtual environment.
HIV Prevention Projects 
for Community-based Organizations
Between July and August 2010, NCHHSTP's 
Division of HIV/AIDS Prevention made awards to 133 
community-based organizations (CBOs) under PS 
10-1003, "HIV Prevention Projects for Community- 
Based Organizations." The Division's new, 5-year 
iteration of its flagship program for directly 
funded CBOs provides HIV prevention services to 
communities disproportionately affected by the HIV 
epidemic (particularly racial/ethnic minorities and 
high-risk groups such as MSM).
The program aims to
• Support the development and implementation 
of effective community-based HIV prevention 
programs that reflect local prevention priorities 
and serve persons at high risk for acquiring or 
transmitting HIV;
• Promote collaboration and coordination of 
HIV prevention efforts among CBOs, health 
departments, and private agencies; and
• Build the capacity of NCHHSTP-funded CBOs 
delivering selected behavioral interventions and/or 
HIV counseling, testing, and referral (CTR) services 
to persons at high risk for acquiring or transmitting 
HIV.
The new CBO program improves upon the previous 
CBO-based program by incorporating critical lessons 
learned. Under the new program CBOs must better 
match planned services to their organizational 
capacity by limiting the number of evidence-based 
interventions and strategies they provide. They 
must also create and maintain referral tracking 
systems and dedicate trained staff to collect, 
manage, analyze, and report the data. Finally, 
funded organizations are required to develop plans 
to incorporate STD, viral hepatitis, and TB screening 
and prevention services into their proposed HIV 
prevention activities.
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Institute of Medicine Review of Viral Hepatitis 
and HHS Interagency Working Group
In January 2010, the Institute of Medicine (IOM) 
issued a report that assessed the effectiveness 
of current prevention and surveillance strategies 
and recommended priorities to guide surveillance, 
research, and program development.
In its report titled, Hepatitis and Liver Cancer: A 
National Strategy f o r  Prevention and Control of 
Hepatitis B and C, the IOM identified multiple barriers 
to hepatitis prevention and care in the United States. 
Viral hepatitis is a leading cause of liver cancer and 
other liver diseases and the most common reason 
for liver transplants in the United States. Yet, there 
is lack of awareness about this serious public health 
challenge, not only among the general public, but 
among health care and social service providers, 
at-risk populations, and policy makers. As a result, 
most of the estimated 4.5 million Americans infected
with hepatitis B and hepatitis C are unaware of 
their infection and not receiving the care they 
need. The IOM panel concluded that this overall 
lack of awareness has resulted in inadequate public 
resources to measure, prevent, and control hepatitis.
In response to the IOM report, HHS convened an 
interagency working group to attack the problem of 
viral hepatitis with a strong, unified approach. The 
working group has been tasked with identifying the 
highest priorities for addressing the viral hepatitis 
epidemic in this country as well as the disease and 
death that it causes. To that end, the workgroup has 
assembled expert panels to develop an HHS Action 
Plan on Viral Hepatitis. CDC and other departmental 
staff are actively engaged in developing the plan. The 
planning process has been inclusive, incorporating 
feedback from HHS subject matter experts, as well as 
input solicited from other government agencies and 
non-governmental organizations.
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Goal 6: Workforce Development and 
Capacity Building
In 2010, NCHHSTP's workforce development 
activities included ongoing and new training and 
career development programs. Ongoing programs 
include the Branch Chiefs' Opportunities for 
Leadership Development (BOLD) initiative and 
the NCHHSTP Summer Fellows Forum. Both are 
led by the center's deputy director. Some newly 
implemented activities include NCHHSTP's Career 
Development Program and the Division of STD 
Prevention Pilot Mentoring Project. Additionally, 
programs were implemented to address goal 6 
of NCHHSTP's Strategic Plan, which focuses on 
attracting and maintaining NCHHSTP's diverse 
workforce.
The BOLD initiative provides opportunities for the 
Center's branch chiefs to strengthen executive 
leadership skills and increase their effectiveness 
in managing NCHHSTP personnel and programs. 
Activities include monthly leadership meetings, 
branch chiefs' quarterly leadership training on the 
Office of Personnel Management's Executive Core 
Qualifications, and supplemental CDC trainings.
The NCHHSTP Summer Fellows Forum is an 8-week 
program that provides summer fellows participating 
in racial and ethnic minority training programs 
with knowledge and skills in conducting public 
health prevention, intervention, surveillance, or 
epidemiologic research in HIV/AIDS, viral hepatitis, 
STDs, and TB. The ultimate goal is to provide a 
pipeline for future public health workers who are 
interested in returning to work at CDC. http:// 
nchhstp.cdc.gov/Fellows/Interns-Fellows.shtml. 
Twenty-four fellows participated in the 2010 summer 
session.
NCHHSTP's Career Development Program was 
developed in the Office of the Director (OD) for 
persons at the GS-13 and GS -14 level or U.S.
Public Health Service Commission Corps Officers 
to serve on a 6-month detail rotation to provide 
opportunities to work in a variety of positions in 
NCHHSTP OD offices— Office of Health Equity, 
Office of the Associate Director for Science, Office 
of the Associate Director for Laboratory Science, 
Office of the Management Officer, Office of
Health Communication Science, and the Office of 
Program Planning and Policy Coordination. The 
goal of the career development program is to 
develop and enhance skills in leadership, program/ 
project coordination and management, budget 
administration, and quality assurance for future 
NCHHSTP leaders.
The Division of STD Prevention Pilot Mentoring 
Project was designed to provide employees with 
mentoring on developing leadership or technical skills 
based on employee self-identified developmental 
needs. The project allows all employees regardless of 
organizational level or position within the Division, 
the opportunity to participate, and provide protégés 
with an avenue to proactively develop their career. 
The project may be expanded to other divisions in the 
near future.
In line with goal 6 of NCHHSTP's Strategic Plan, 
one major workforce development activity was the 
creation of two advisory groups to provide advice 
to the NCHHSTP Director and Deputy Director 
concerning strategies, goals, and best and promising 
practices for workforce development, succession 
planning, and work life programs. The first group, 
Workforce Development Champions Work Group, 
includes representatives from each division within 
NCHHSTP, and meets monthly to discuss current and 
new strategies to enhance workforce development 
activities. The other advisory group— the Excellence 
in Workforce Development, Capacity Building 
and Succession Planning Advisory Group— meets 
quarterly and includes senior leaders from HHS 
Atlanta Human Resources Center, and CDC's Human 
Capital Management Office, and Offices of Diversity 
Management and Equal Employment Opportunity; 
and Safety, Health, and Environment.
In an effort to attract a more diverse workforce, 
linkages were established with external stakeholders 
from Historically Black Colleges and Universities, 
National Association of County and City Health 
Officers, Association of State and Territorial Health 
Officers, and the Council of State and Territorial 
Epidemiologists. Additionally, NCHHSTP appointed 
staff to serve in CDC's Recruiter Cadre to recruit 
underrepresented minorities to intern and work 
in NCHHSTP. Also in 2010, NCHHSTP actively 
participated with CDC's Diversity Council and the
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Equal Employment Opportunity Advisory Council 
(EEOAC) monthly.
NCHHSTP is also committed to mentoring young 
scientists who are interested in epidemiologic 
and prevention research. The extramural Minority 
HIV/AIDS Research Initiative (MARI), initiated in 
2002, creates partnerships between NCHHSTP 
epidemiologists and researchers who are members 
of minority races and ethnicities and who work in 
communities of color. MARI funds epidemiologic and 
prevention studies of HIV in communities of color 
and encourages the career development of young 
investigators.
To date, MARI has supported 19 junior researchers 
who are conducting HIV prevention research in 
highly-affected minority communities. Their 
research has included studies focusing on housing 
challenges and HIV care access for HIV-infected 
persons; resiliency factors among gay, black men
at high risk of HIV infection; feasibility of HIV 
testing and referrals in pharmacies that provide 
clean needles for injection drug users; barriers and 
facilitators for HIV testing among pregnant Latinas; 
and exploring youth and family communications 
that promote improved sexual health. MARI 
research findings have been presented at national 
and international scientific meetings, shared with 
community partners, and published in peer-reviewed 
journals. The MARI network of investigators 
continues to expand and result in successful cross­
collaborations for HIV prevention research in 
minority communities.
NCHHSTP also has had a number of Epidemic 
Intelligence Service (EIS) officers. Six officers joined 
the center in FY 2010. The EIS is the country's critical 
epidemiology training service, working to combat 
the causes of major epidemics.
A Year in Review: 
Scientific Findings
Research is an important part of CDC's 
comprehensive approach to prevention, and 
excellence in science is a strategic priority. This 
priority mandates that we practice evidence-based 
science grounded in sound, peer-reviewed research, 
and that we ensure a strong science base for public 
health action.
NCHHSTP conducts extensive biomedical and 
behavioral research to better understand the 
complex factors that lead to epidemics, to evaluate 
methods of testing and treatment, and to examine 
strategies to eliminate health disparities. All 
extramural and intramural research activities 
conducted or supported by NCHHSTP are subject to 
external peer review, ensuring rigor and quality and 
that research funds support the most meritorious 
research ideas and projects. External peer review 
improves our science by providing expert feedback 
on quality, productivity, science, and direction.
Three advisory boards regularly provide peer review 
of NCHHSTP programs: the Advisory Council for the 
Elimination of Tuberculosis, which advises on the 
center's TB prevention and control programs; the 
CDC/HRSA HIV/AIDS Advisory Committee on HIV 
and STD Prevention and Treatment, which reviews 
HIV, STD, and viral hepatitis programs; and the 
Office of Infectious Diseases (OID) Board of Scientific 
Counselors, which focuses on all OID programs, 
including those of NCHHSTP.
Research findings are published in peer-reviewed 
journals. NCHHSTP staff published, or have in-press, 
a number of journal articles, book chapters, books, 
guidelines, and other publications. Included below 
are some highlights from FY 2010.
HIV Studies and Research 
U.S. Extended Pre-Exposure 
Prophylaxis Safety Trial 
Among Men Who Have Sex with Men
The approach of taking a daily antiretroviral drug 
to try to prevent HIV infection is known as pre­
exposure prophylaxis, or PrEP, and studies around 
the world are currently underway to determine if it 
is effective in reducing HIV infection among persons 
at high risk, including MSM, injection drug users, and 
heterosexual men and women. Preliminary findings 
from the first CDC PrEP study to examine the clinical 
and behavioral safety of tenofovir taken daily for HIV 
prevention among MSM suggest no significant safety 
concerns in this population.
The study was conducted by NCHHSTP's Division of 
HIV/AIDS Prevention in collaboration with the San 
Francisco Department of Health, the AIDS Research 
Consortium of Atlanta, and Fenway Community 
Health in Boston. The trial examined whether a 300 
mg tablet of tenofovir disoproxil fumarate taken 
daily was safe among 400 HIV-negative MSM in San 
Francisco, Atlanta, and Boston. Study results were 
presented at the International AIDS Conference 
in Vienna, Austria, in July 2010. This safety study 
suggests that the strategy may be well tolerated in 
MSM, should it prove effective.
In November, the National Institutes of Health 
(NIH) announced results of another PrEP trial— the 
international iPrEx trial examining whether drugs 
used to treat HIV can also help prevent HIV infection. 
Trial findings showed that a once-daily pill containing 
tenofovir plus emtricitabine was safe and provided an 
average of 44% (95% Confidence Interval [CI]; 15% - 
63%) additional protection against HIV infection to 
MSM and transgendered women who have sex with 
men, who also received a comprehensive package 
of prevention services. These services included 
use of condoms, monthly HIV testing, counseling, 
and management of other sexually transmitted 
infections.















Investigation of Increased Diagnoses 
of HIV Infection 
Among Young Black Men 
Who Have Sex with Men in Milwaukee
An NCHHSTP investigation of a 144% increase in HIV 
diagnoses among young black MSM in Milwaukee 
found this likely reflected increased HIV transmission 
among young black MSM, rather than intensified HIV 
testing. The findings were published in the July 2010 
Morbidity and Mortality Weekly Report.
This investigation found that increases in 
HIV diagnoses in Milwaukee preceded the 
implementation of intensified HIV testing, so 
intensified testing could not explain the increase. The 
investigation also found that increases in primary 
and secondary syphilis diagnoses preceded the 
increases in HIV diagnoses among young black MSM, 
suggesting that changes in risk behaviors or sexual 
networks among this group may have facilitated the 
spread of HIV.
Young, HIV-infected MSM in Milwaukee County 
who were diagnosed from January 2006-June 2009 
were interviewed to identify socioenvironmental 
factors that might contribute to HIV transmission. 
Low perceived community acceptance of MSM, 
internalized homophobia, sex with older men, 
same-race sexual partnerships, and socioeconomic 
instability were common among men interviewed. 
The investigation also revealed that black MSM were 
three times more likely than MSM from other racial/ 
ethnic groups to report that their families' reactions 
to their sexual orientation affected their living 
arrangements. These findings suggest that black 
MSM may encounter greater stigma against same- 
sex behaviors than other MSM.
Stigma, unstable housing, and socioeconomic 
instability may foster high-risk sexual behaviors 
that enhance exposure to HIV. Young age at HIV 
diagnosis with concurrent AIDS diagnosis suggests 
that some black MSM may have contracted HIV 
close to the time of their first homosexual encounter, 
underscoring the need for early interventions for HIV- 
infected MSM and young MSM at risk for HIV.
As a result of this investigation, the City of 
Milwaukee Health Department, in collaboration with 
community partners, is developing a comprehensive, 
peer-focused action plan to reduce ongoing HIV 
transmission by combating homophobia, promoting 
education that affirms the sexuality of MSM, and 
integrating HIV and syphilis prevention efforts. 
NCHHSTP encourages examinations of SDH 
to prevent HIV transmission among vulnerable 
populations.
Study Shows That Heterosexual Women in the 
Southeast May Be at Increased Risk for HIV 
Infection
The behavioral risk factors for HIV infection were 
assessed among African-American women in rural 
counties in Alabama and North Carolina and among 
Latinas in Florida.
Researchers recruited 1,527 sexually active women 
without known HIV infection using multiple sampling 
methods. Participants completed a computer- 
administered questionnaire and were tested for HIV 
infection. A subset of participants also completed a 
qualitative, semi-structured interview.
Overall, 26% of the participants (24% in North 
Carolina, 22% in Alabama, and 31% in Florida) 
reported that they had engaged in unprotected 
anal intercourse in the past 12 months. Correlates
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of this behavior included being unemployed, 
having engaged in exchange sex, having engaged 
in unprotected vaginal intercourse, binge drinking, 
and ever being pregnant. Only two women tested 
HIV-positive in the study suggesting that most of the 
women's sexual partners were not infected with HIV.
These findings indicate that the potential for HIV 
infection is very high among women in the Southeast 
if HIV-positive men enter the women's sexual 
networks. The findings will inform the design of 
behavioral interventions for heterosexual women 
of color.
Viral Hepatitis Studies and Research 
Mass-spectrophotometric Analysis of Full 
Length Genomes of Hepatitis B Virus
Genotyping hepatitis B virus is critical to the tracking 
of hepatitis B infections and for predicting both 
the risk of progression of chronic hepatitis B and 
outcomes of antiviral therapy. However, current 
methods for genotyping hepatitis B virus are 
laborious and costly.
Laboratorians in the Division of Viral Hepatitis have 
developed and evaluated an automated approach 
based on matrix-assisted, laser desorption ionization- 
time-of-flight mass spectrometry that should 
provide accurate and rapid HBV genotyping. More 
widespread adoption of this technique may help to 
reduce the cost of public health HBV surveillance 
and may help improve the clinical management of 
persons with chronic HBV infection. The technique 
may decrease the length of time required to report 
the genotype to health care providers so that 
patients can receive earlier treatment.
The Division has established collaborations with 
clinical centers of excellence in the management of 
chronic hepatitis B patients to study the application 
of this new methodology for routine patient care.
Evaluation of the Performance 
Characteristics of Serological 
Assays to Diagnose Acute Hepatitis
In the United States, infection with hepatitis E virus 
(HEV) appears common, although clinical disease 
caused by it seems rare. Underdiagnosis of hepatitis 
E may contribute to the low numbers of clinical 
cases. A number of commercial serological assays for 
detecting immunoglobulin M antibodies to hepatitis 
E virus have become available but their performance 
characteristics have not been fully evaluated.
Division of Viral Hepatitis laboratorians undertook 
and completed such an evaluation. The evaluation 
identified assays with the best sensitivity and 
specificity characteristics and provided information 
so that diagnostic and public health laboratories 
can select the best-performing assays that will 
assist further epidemiologic study of incident HEV 
infection.
Treatment of Hepatitis C Virus Infection 
in Patients Coinfected with HIV
Liver disease due to HCV infection is a leading cause 
of non-AIDS-related morbidity and mortality in 
HIV-infected patients; however, many studies show 
that only a small proportion of eligible patients 
are offered treatment for HIV coinfection and the 
predictors of receiving treatment are not fully 
understood. In a recent study, the frequency of, 
and predictors for, initiation of treatment for HCV 
infection among HCV/HIV-coinfected patients 
enrolled in the HIV Outpatient Study (HOPS) during 
1999-2007 were assessed.
The results showed low levels of treatment for HCV 
infection among the cohort, although some variation 
was found by race/ethnicity and clinical characteristic 
among persons initiating treatment. For patients 
starting observation in 1999-2001, 2002-2004 
and 2005-2007, 5%, 11% and 21% of patients 
initiated treatment during the first year of follow-up, 
respectively. Of 22 patients in the cohort who had 
hepatic-related deaths, only 7 (32%) received anti- 
HCV treatment. The study points to the importance 
of treating HCV infection in HCV/HIV-coinfected 
patients, given the increased risk of accelerated end­
stage liver disease.
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Hepatocellular Carcinoma 
Increasing in United States
Liver cancer, primarily hepatocellular carcinoma 
(HCC), is the third leading cause of death from cancer 
worldwide and the ninth leading cause of cancer 
deaths in the United States. Chronic HBV and HCV 
infections account for an estimated 78% of global 
HCC cases. To determine trends in HCC incidence 
in the United States, Division of Viral Hepatitis 
researchers analyzed data for the period 2001-2006 
from CDC's National Program of Cancer Registries 
and the National Cancer Institute's Surveillance, 
Epidemiology, and End Results surveillance system.
The analysis showed that the average annual 
incidence rate of HCC during 2001-2006 was 3.0 
per 100,000 persons and increased significantly 
from 2.7 per 100,000 persons in 2001 to 3.2 in 2006. 
The average annual percentage change (APC) in 
incidence rate was 3.5%. The largest increases in HCC 
incidence rates were among whites (APC=3.8), blacks 
(APC=4.8), and persons aged 50-59 years (APC=9.1), 
revealing a continuation of long-term increases in 
HCC incidence and HCC racial/ethnic disparities.
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Hepatitis C Testing Practices and Prevalence 
in a High-risk, Urban Ambulatory Care Setting
Approximately 3.2 million persons are chronically 
infected with HCV in the United States; most are not 
aware of their infection. A team led by investigators 
from Boston University, Montefiore Medical Center, 
and NCHHSTP examined HCV testing practices in 
an urban ambulatory care clinic to determine which 
patient characteristics were associated with HCV 
testing and positivity and to estimate the prevalence 
of HCV infection in a high-risk urban population.
The study subjects were patients included in the 
baseline phase of the Hepatitis C Assessment and 
Testing Project, a serial cross sectional study of HCV 
screening strategies among patients with a clinic 
visit to Montefiore Medical Center in early 2008. 
Demographic information, laboratory data, and ICD- 
9 diagnostic codes for visits in the previous 5 years 
were extracted from the electronic medical record. 
Risk factors for HCV were defined based on birth 
date, ICD-9 codes, and laboratory data.
The prevalence of HCV infection was estimated 
assuming that untested subjects would test positive 
at the same rate as tested subjects, based on risk 
factors. Of 9,579 subjects examined, 3,803 (39.7%) 
had been tested for HCV and 438 (11.5%) were 
positive. The overall prevalence of HCV infection was 
estimated to be 7.7%. Risk factors associated with 
being tested and with anti-HCV positivity included 
being born in the birth cohort (1945-64) associated 
with highest prevalence of HCV, substance abuse,
HIV infection, alcohol abuse, diagnosis of cirrhosis, 
end-stage renal disease, and alanine transaminase 
elevation. In this high-risk, urban population, a 
sizable minority of patients was tested for HCV and 
the prevalence of HCV infection was high. Physicians 
appeared to employ a risk and clinically based 
screening strategy to identify HCV infection.
Based on these findings, the authors proposed that 
HCV screening recommendations for populations 
such as the one under study (a high-risk, urban 
population) be expanded to include those born from 
1945 through 1964. People born between 1945 and 
1964 have a higher risk of HCV infection than those 
born other periods.
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STD Research and Studies
Dual Treponemal/Non-Treponemal 
Point of Care Tests
Division of STD Prevention researchers have 
been involved in the development of a rapid 
immunofiltration (flow-through) test for the 
simultaneous detection of treponemal and non- 
treponemal antibodies in the serum of patients 
with syphilis. The assay is rapid, inexpensive, and 
requires limited expertise in interpreting the results.
A positive test is characterized by the appearance of 
three red/magenta spots within 2-10 minutes.
Division of STD Prevention researchers examined 
376 banked serum samples from the Georgia 
Public Health Laboratory using three tests— the 
flow-through test, the rapid plasma reagin (RPR) 
test, and the Treponema pallidum passive particle 
agglutination assay. The test results indicated that 
the dual treponemal and non-treponemal assay 
could be used as a screen and confirmatory test 
for the serological diagnosis of syphilis in remote 
or resource-poor settings where there is a need 
to provide counseling and treatment at the initial 
consultation. The study was published in Sexually 
Transmitted Infections, 2010.
Internet Partner Notification for Syphilis
The Internet has become a common venue for 
meeting sex partners and planning participation in 
risky sexual behavior. The Division of STD Prevention, 
with colleagues at Washington, D.C.'s Department of 
Health, evaluated the D.C. Department of Health's 
Internet-based Partner Notification (IPN) program 
for early syphilis infections.
Records were analyzed from all early syphilis 
investigations initiated during January 2007-June 
2008. Internet partners were defined as sex partners 
for whom syphilis exposure notification was initiated 
by e-mail because no other locating information 
existed. From the 361 early syphilis patients found 
in the study, a total of 888 sex partners were 
investigated, of which 381 (43%) were via IPN.
IPN led to an 8% increase in the overall number of 
syphilis patients with at least one treated sex partner, 
26% more sex partners being medically examined
and treated if necessary, and 83% more sex partners 
notified of their STD exposure. The study was 
published in Sexually Transmitted Diseases, 2010.
New Statistical Method for Evaluation 
of NAAT Testing for Chlamydia
In collaboration with scientific colleagues, the Division 
of STD Prevention has developed a new statistical 
model called the multiple latent variable model, which 
can be used to estimate test performance parameters 
in the absence of a gold-standard test. The model 
was applied to evaluate the sensitivity and specificity 
of nucleic acid amplification tests for detecting 
Chlamydia trachomatis and the manuscript describing 
this work was deemed the 2010 best statistical paper 
(theoretical category) written by a CDC statistician in 
the CDC/ATSDR Statistical Science Awards Program. 
The study was published in Statistics in Medicine 
(2009;28[3]:441-61).
Tuberculosis Studies and Research
Improving Diagnosis of Tuberculosis in HIV- 
Infected Persons
TB is the most common cause of death in people with 
HIV. Routine TB screening for those infected with HIV 
is recommended, but diagnosing TB in people with 
HIV is difficult and evidence is lacking about how best 
to do the screening.
With funding from the United States Agency for 
International Development and support from the 
President's Emergency Plan for AIDS Relief, the 
Division of Tuberculosis Elimination enrolled 2,000 
people with HIV from 8 clinics in Cambodia, Thailand, 
and Vietnam in a study designed to determine how 
best to screen for, and diagnose TB in, people with 
HIV. The study sought to identify a highly sensitive 
approach to TB screening in people with HIV that 
could be used in resource-limited settings and to 
determine what combination of diagnostic tests 
would be most useful to diagnose TB.
The study found that asking patients only about the 
presence of a cough for at least 2 weeks, which is the 
internationally recommended approach, failed to 
detect over two-thirds of patients with TB, placing 
them at increased risk for death. However, the
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percentage of missed TB diagnoses dropped to less 
than 10% if health care workers asked about three 
specific symptoms (cough or fever of any duration 
and night sweats for at least 3 weeks). Patients who 
reported none of the three symptoms did not require 
additional testing and could be started safely on 
HIV treatment and TB prevention medication. Study 
results were published in the New England Journal of 
Medicine in February 2010.
In addition, WHO and the Division of Tuberculosis 
Elimination conducted a meta-analysis of TB 
screening studies, including this study and studies 
from other parts of the world. The results confirmed 
the study findings. WHO convened a meeting in 
January 2010 to update guidelines for TB screening 
and prevention in people with HIV and eliminated 
screening based solely on chronic cough, replacing it 
with screening based on a combination of symptoms, 
similar to those noted above.
Improving TB Prevention for 
HIV-infected Persons in TB-endemic Countries
A study by NCHHSTP's Division of Tuberculosis 
Elimination suggests that a simple change in the drug 
regimen used to prevent active TB disease among 
HIV-positive people who test positive for latent TB 
infection can greatly reduce TB-related illness.
HIV-infected persons who have also been infected 
with tuberculosis have a very high risk of progressing 
to TB disease. WHO recommends that HIV-infected 
persons receive 6 months of isoniazid preventive 
therapy in order to reduce their risk of TB disease. 
However there has been a longstanding concern that 
6 months of preventive therapy may be insufficient 
in TB-endemic countries because of the high risk of 
reinfection with TB.
NCHHSTP's Division of Tuberculosis Elimination 
recently concluded a large clinical trial in which 
preventive therapy was provided for 3 years to 
see if TB was better prevented among 2,000 
HIV-infected adults. The study found continuing 
isoiniazid preventive therapy reduced the risk of TB 
by half, compared to the 6-month therapy. Among 
participants who were tuberculin skin test-positive 
and received continuous preventive therapy, there 
was a 92% reduction in TB.
These findings resulted in substantial changes to 
the WHO's 2010 revision of the WHO isoniazid 
preventive therapy recommendations. If these new 
recommendations are adopted by member nations, 
over 30 million HIV-infected persons living in TB- 
endemic countries stand to benefit. Botswana's 
Ministry of Health is currently reviewing its isoniazid 
preventive therapy policy as a result of the trial it 
conducted in collaboration with CDC.
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NCHHSTP Budget
Funding for most NCHHSTP programs has remained 
roughly level over the past 5 years. The HIV program, 
however, has increased since 2006. (See figure 1.)
Of NCHHSTP's $1 billion domestic budget, the 
majority of funds, 71%, goes to domestic HIV 
prevention programs, with the rest distributed to 
TB, STD and viral hepatitis prevention programs.
(See figure 2.) The majority of the overall domestic 
budget funds, about 84%, was distributed 
extramurally to state and local health departments, 
nongovernmental agencies, universities and other 
partners. (See figure 3.)
NCHHSTP receives funding from the HIV, STD,
TB, and viral hepatitis account in the Labor-HHS 
appropriation to support its programs. Other 
critical sources of support in FY 2010 included the 
budget activities for Emerging Infections ($8.8 
million) and Food Safety (for hepatitis A) (nearly 
$700,000). NCHHSTP also received $30 million from 
the Affordable Care Act's Prevention and Public
Health Fund in FY 2010 for activities to help carry 
out the President's National HIV/AIDS Strategy. And 
NCHHSTP received $3.4 million through the HHS 
Minority AIDS Initiative.
Performance Indicators
NCHHSTP's portfolio has been reviewed by the 
Office of Management and Budget (OMB) and found 
to be performing effectively. Results are available at 
www.expectmore.gov. In collaboration with OMB, 
NCHHSTP has established 37 performance measures 
to assess to extent to which our efforts in HIV/AIDS, 
viral hepatitis, STD, and TB prevention result in 
real changes in health outcomes. These indicators 
reveal that progress is being made; data on 41% of 
the indicators have improved since 2002. NCHHSTP 
is working to improve the outcomes in those areas 
where progress has not been made and to establish 
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Figure 2: Domestic HIV, Viral Hepatitis, STD, and TB Prevention
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Figure 3: Domestic HIV, Viral Hepatitis, STD, and TB Prevention 
Extramural and Intramural Obligations, FY 2010*
Extramural
84 %
Total: $1  billion
Intramural
14%
Transfers to Other 
Federal Agencies 
2%
*Excludes Gift Fund, CRADA, Royalties and Reimbursable Funding; 
includes Affordable Care Act Prevention and Public Health Funds
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APPENDIX
PERFORMANCE MEASURES FOR HIV/AIDS, VIRAL HEPATITIS, STD, 
AND TB PREVENTION
Domestic HIV/AIDS Prevention
GOAL 1: DECREASE THE ANNUAL HIV INCIDENCE RATE
Measure Baseline Result
1. Decrease the annual HIV incidence. 5 6 ,3 0 0  (2 0 0 6 ) Not Available
2. Decrease the number of pediatric AIDS cases. 118 41 (2 0 0 8 )
3. Reduce the black:white rate ratio of H IV/A IDS  
diagnoses.*
10.33:1 9 .2 :1  (2 0 0 8 )
4. Reduce the Hispanic:white rate ratio 
of H IV /A IDS diagnoses.*
4 .1:1 3 .4 9 :1  (2 0 0 8 )
5. Increase the number of states with mature, 
name-based HIV surveillance systems.
29 39
6 . Increase the percentage of HIV prevention 
program grantees using Program Evaluation 
and Monitoring System (PEMS) to monitor 
program implementation.
0  (2 0 0 6 ) 97%
7. Increase the number of evidence-based 
prevention interventions that are packaged 
and available for use in the field by prevention 
program grantees.
7 2 1
8 . Increase the number of agencies trained 
each year to implement Diffusion of Effective 5 3  9 3 5  
Behavior Interventions (DEBIs).
Data Source: Measure 1 - HIV/AIDS Incidence Surveillance in 34 states. Measures 2 - 5 - HIV/AIDS Reporting System (eHARS). Measure 6 - Program 
Evaluation and Monitoring System (PEMS). Measure 7 - Replicating Effective Programs (REP) Project data. Measure 8 - Diffusion o f Effective 
Behavioral Interventions (DEBI) Tracking Database.
* Data for these measures is derived from 33 states with mature, stable HIV case surveillance. These states are: Alabama, Alaska, Arizona, Arkansas, 
Colorado, Florida, Idaho, Iowa, Indiana, Kansas, Louisiana, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Jersey, New York,
New Mexico, North Carolina, North Dakota, Ohio, Oklahoma, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, 
and Wyoming.
GOAL 2: DECREASE THE RATE OF HIV TRANSMISSION BY HIV-INFECTED PERSONS
Measure Baseline Result
1. Decrease the rate of HIV transmission by 
HIV-infected persons.
5% (2 0 0 6 ) Not Available
2. Decrease risky sexual and drug using behaviors 
among persons a t risk for transm itting HIV.
Not Available Not Available
Data Source: Measure 1 - Calculations o f HIV incidence and prevalence, utilizing HIV/AIDS Incidence Surveillance System and special prevalence 
studies; Measures 2 - Medical Monitoring Project (MMP).
• Baseline established for 2002, unless otherwise indicated
• Result established for 2009 data, unless otherwise indicated
• Progress reflects performance data available as o f 2-1-2011.
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GOAL 3: DECREASE RISKY SEXUAL AND DRUG USING BEHAVIORS AMONG PERSONS AT RISK FOR ACQUIRING HIV
Measure Baseline Result
1. Decrease risky sexual and drug-using behaviors 
among persons a t risk for acquiring HIV.
Men who have sex with men (M S M ) -  47% (2 0 0 4 )  
High Risk Heterosexual (HRH) -  8 6 % (2 00 7 )  
Injection Drug Users (IDU) -  72%  (2 0 0 5 )
M SM -  54%  (2 0 0 8 )  
HRH -  Not Available 
IDU -  Not Available
2. Increase the proportion of persons a t risk for 
HIV who received HIV prevention interventions.
M SM -  18.9%  (2 0 0 4 )  
HRH -  12.5%  (2 0 0 7 )  
IDU -  29.7%  (2 0 0 5 )
M SM -  17.6% (2 0 0 8 )  
HRH -  Not Available 
IDU -  Not Available
Data Source: Measures 1 and 2 -  National HIV Behavior Surveillance (NHBS) System.
GOAL 4: INCREASE THE PROPORTION OF HIV-INFECTED PEOPLE IN THE UNITED STATES WHO KNOW THEY ARE INFECTED
Measure Baseline Result
1. Increase the proportion of HIV-infected 
people in the United States who know they 
are infected.
74.5%  (2 0 0 3 ) 79% (2 0 0 6 )
2. Increase the proportion of persons with 
HIV-positive test results from publicly funded 
counseling and testing sites who receive their 
test results.
81% 92%  (2 0 0 8 )
3. Increase the proportion of people with HIV 
diagnosed before progression to A ID S.*
78.1% 82.1%  (2 0 0 8 )
Data Source: Measure 1 -  Special studies using eHARS. Measure 2 - Counseling, Testing, and Referral System (CTR) ^  Program Evaluation 
and Monitoring System (PEMS). Measure 3 - eHARS.
* Data for these measures is derived from 33 states with mature, stable HIV case surveillance. These states are: Alabama, Alaska, Arizona, Arkansas, 
Colorado, Florida, Idaho, Iowa, Indiana, Kansas, Louisiana, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Jersey, New York,
New Mexico, North Carolina, North Dakota, Ohio, Oklahoma, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, 
and Wyoming.
GOAL 5: INCREASE THE PROPORTION OF HIV-INFECTED PERSONS WHO ARE LINKED TO PREVENTION AND CARE SERVICES
Measure Baseline Result
1. Increase the percentage of HIV-infected 
persons in publicly funded counseling and 
testing sites who were referred to Prevention 
Counseling and Referral Services (PCRS).
Not Available Not Available
2. Increase the percentage of HIV-infected 
persons in publicly funded counseling and 
esting sites who were referred to medical 
care and attended their first appointment.
Not Available Not Available
3. Increase the percentage of HIV-infected 
persons in publicly funded counseling and 
testing sites who were referred to HIV 
prevention services.
Not Available Not Available
4. Increase the percentage of HIV-infected 
persons in medical care who initiated medical 
care within three months of diagnosis.
Not Available Not Available
Data Source: Measures 1 - 3 -  Program Evaluation and Monitoring System (PEMS). Measure 4 - Medical Monitoring Project (MMP).
• Baseline established for 2002, unless otherwise indicated
• Result established for 2009 data, unless otherwise indicated
• Progress reflects performance data available as o f 2-1-2011.
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Viral Hepatitis Prevention
GOAL 6: REDUCE THE RATES OF VIRAL HEPATITIS IN THE UNITED STATES
Measure Baseline Result
1. Reduce the rate of new cases of hepatitis A 
(per 1 00 ,00 0  population). 1 1 .3 /1 0 0 ,0 0 0  (1 99 7 ) 0 .9 /1 0 0 ,0 0 0  (2 0 0 8 )
2. Reduce the rate of new cases of hepatitis B 
(per 1 00 ,00 0  population). 2 .6 /1 0 0 ,0 0 0  (2 0 0 3 ) 1 .3 /1 0 0 ,0 0 0  (2 0 0 8 )
3. Increase the proportion of individuals knowing 
their hepatitis C virus infection status. 50%  (2 0 0 4 ) 49%  (2 0 0 2 -2 0 0 7 )
4. Increase the number of areas reporting chronic 
hepatitis C virus infections to CDC to 5 0  states 
and New York City and District of Columbia.
19 areas (2 0 0 3 ) 33  areas (2 0 0 8 )
Data Source: Measures 1, 2, 4 -  The National Notifiable Diseases Surveillance System (NNDSS); Measure 3 -- The National Health 
and Nutrition Examination Survey (NHANES).
STD Prevention
GOAL 7: REDUCE THE RATES OF NON-HIV SEXUALLY TRANSMITTED DISEASES (STDS) IN THE UNITED STATES
Measure Baseline Result
1. Reduce pelvic inflammatory disease in the U.S. 197 ,00 0 100,000
2. Reduce the prevalence of chlamydia among 
high-risk women under age 25.
10.1% 11.3%
3. Reduce the prevalence of chlamydia among 
women under age 2 5 , in publicly funded family 
planning clinics.
5.6% 7.4% (2 0 0 8 )
4. Reduce the incidence of gonorrhea in women 
aged 15 to 4 4  (per 1 0 0 ,00 0  population).
2 7 9 /1 0 0 ,0 0 0 2 5 5 /1 0 0 ,0 0 0
5. Eliminate syphilis in the U.S. 2 .4 /1 0 0 ,0 0 0 4 .6 /1 0 0 ,0 0 0
6. a) Reduce the incidence of P&S syphilis in men 
(per 1 0 0 ,00 0  population). *
5 .7 /1 0 0 ,0 0 0
(2 0 0 6 )
7 .8 /1 0 0 ,0 0 0
6. b) Reduce the incidence of P&S syphilis in 
women (per 1 0 0 ,00 0  population).
1.1 /1 0 0 ,0 0 0 1 .4 /1 0 0 ,0 0 0
7. Reduce the incidence of congenital syphilis 
(per 1 0 0 ,00 0  live births).
10.2 /1 0 0 ,0 0 0 10.0 /1 0 0 ,0 0 0
8. Reduce the racial disparity of P&S syphilis 
(reported ratio is black:white).
8.1:1 9 .0 :1
Data Source: Measure 1 -  The National Disease and Therapeutic Index (NDTI) (IMS Health). Measure 2 -- The U.S. Department o f Labor, National 
Job Training Program; CDC, IPP Chlamydia Prevalence Monitoring Project. Measure 3 -- CDC, IPP Chlamydia Prevalence Monitoring Project.
Measure 4 - 8 -- STD Morbidity Surveillance System, CDC.
*In FY 2002, the incidence of P&S syphilis in men was 3.8 per 100,000 (initial 2002 baseline). However, because an outbreak o f syphilis among men who 
have sex that occurred after 2002 has driven up the male syphilis rates, CDC is reporting a new baseline for 2006.
• Baseline established for 2002, unless otherwise indicated
• Result established for 2009 data, unless otherwise indicated
• Progress reflects performance data available as o f 2-1-2011.
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TB Prevention
GOAL 8: DECREASE THE RATE OF CASES OF TUBERCULOSIS AMONG U.S.-BORN PERSONS IN THE UNITED STATES
Measure Baseline Result
1. Decrease the rate of cases of TB among 
U.S.-born persons (per 1 0 0 ,00 0  population).
2 .9 1.7
2. Increase the percentage of TB patients who 
complete a course of curative TB treatm ent 
within 1 2  months of initiation of treatm ent 
(some patients require more than 1 2  months).
80.9% 84.3%  (2 0 0 7 )
3. Increase the percentage of TB patients with 
initial positive cultures who also have drug 
susceptibility results.
93.0% 95.7%
4. Increase the percentage of contacts of 
infectious (Acid-Fast Bacillus (AFB) 
smear-positive) cases that are placed on 
treatm ent for latent TB infection and complete 
a treatm ent regimen.
41.0% 64.3%  (2 0 0 7 )
Data Source: Measures 1 -  3 - The National TB Surveillance System. Measure 4 -The National TB Surveillance System and the national Aggregate 
Reports for TB Program Evaluation.
Overarching NCHHSTP Efficiency Measure
Efficiency Measure1 Baseline Result
1. Increase the efficiency of core H IV/A IDS  
surveillance as measured by the cost per 
estimated case of H IV /A ID S diagnosed 
each year.
$1 ,3 57  (2 0 0 3 ) $ 77 2  (2 0 0 8 )
Data Source: Measure 1 - HIV/AIDS Reporting System (HARS) is used to collect state HIV and AIDS data, financial assistance information is drawn 
from administrative records and adjusted for inflation.
• Baseline established for 2002, unless otherwise indicated
• Result established for 2009 data, unless otherwise indicated
• Progress reflects performance data available as o f 2-1-2011.
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